Creative Planning Increases Position in STAAR Surgical (NASDAQ:STAA)

Creative Planning lifted its holdings in shares of STAAR Surgical (NASDAQ:STAA) by 8.0% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 5,524 shares of the medical instruments supplier’s stock after acquiring an additional 408 shares during the quarter. Creative Planning’s holdings in STAAR Surgical were worth $205,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also modified their holdings of the business. Covestor Ltd boosted its stake in STAAR Surgical by 38.9% in the first quarter. Covestor Ltd now owns 2,690 shares of the medical instruments supplier’s stock valued at $103,000 after acquiring an additional 754 shares during the period. Canada Pension Plan Investment Board acquired a new position in shares of STAAR Surgical in the second quarter worth $129,000. Larson Financial Group LLC bought a new stake in STAAR Surgical in the second quarter worth $130,000. Contravisory Investment Management Inc. acquired a new position in shares of STAAR Surgical during the third quarter valued at about $214,000. Finally, Truist Financial Corp acquired a new position in shares of STAAR Surgical during the second quarter valued at about $268,000. 96.70% of the stock is owned by hedge funds and other institutional investors.

STAAR Surgical Stock Up 2.8 %

Shares of NASDAQ STAA opened at $30.42 on Tuesday. STAAR Surgical has a twelve month low of $26.66 and a twelve month high of $52.68. The company’s fifty day moving average is $31.59 and its 200-day moving average is $37.75. The stock has a market cap of $1.50 billion, a price-to-earnings ratio of 69.14 and a beta of 0.61.

Analyst Ratings Changes

Several analysts have recently weighed in on STAA shares. Needham & Company LLC reaffirmed a “hold” rating on shares of STAAR Surgical in a report on Thursday, October 31st. Stifel Nicolaus decreased their price target on shares of STAAR Surgical from $50.00 to $44.00 and set a “buy” rating on the stock in a research note on Monday, August 26th. Canaccord Genuity Group decreased their price target on shares of STAAR Surgical from $41.00 to $31.00 and set a “hold” rating on the stock in a research note on Friday, November 1st. BTIG Research increased their price target on shares of STAAR Surgical from $46.00 to $53.00 and gave the company a “buy” rating in a research note on Monday, July 15th. Finally, Morgan Stanley cut shares of STAAR Surgical from an “equal weight” rating to an “underweight” rating and decreased their price target for the company from $50.00 to $37.00 in a research note on Monday, July 15th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat.com, STAAR Surgical has an average rating of “Hold” and an average price target of $43.33.

STAAR Surgical Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.